

# Barbara Schmidt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7209199/publications.pdf>

Version: 2024-02-01

34  
papers

892  
citations

687363

13  
h-index

501196

28  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1575  
citing authors

#	ARTICLE	IF	CITATIONS
1	Contribution of High Viral Loads, Detection of Viral Antigen and Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity. <i>Journal of Infectious Diseases</i> , 2022, 225, 190-198.	4.0	13
2	Antibodies against viral nucleo-, phospho-, and X protein contribute to serological diagnosis of fatal Borna disease virus 1 infections. <i>Cell Reports Medicine</i> , 2022, 3, 100499.	6.5	16
3	Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination. <i>IScience</i> , 2022, 25, 103694.	4.1	5
4	Mouthrinses against SARS-CoV-2 " High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial. <i>Virus Research</i> , 2022, 316, 198791.	2.2	18
5	Unexpectedly high seroprevalance of Kaposi's sarcoma-associated herpesvirus (HHV-8) in patients with stage IV melanoma. <i>European Journal of Cancer</i> , 2022, 172, 51-52.	2.8	1
6	A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. <i>Infection</i> , 2021, 49, 75-82.	4.7	118
7	Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 97-108.	2.8	44
8	Exploring Viral Interference Using Peptides: Molecular Determinants of HIV-1 Inhibition by a Peptide Derived from Human Pegivirus-1 Envelope Protein E2. <i>ChemMedChem</i> , 2021, 16, 1290-1296.	3.2	4
9	Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson's disease: Balancing immunosuppression. <i>International Journal of Infectious Diseases</i> , 2021, 103, 624-627.	3.3	15
10	SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19. <i>Infection</i> , 2021, 49, 739-746.	4.7	47
11	Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. <i>Nature Communications</i> , 2021, 12, 1439.	12.8	39
12	Evaluation of a Broad Panel of SARS-CoV-2 Serological Tests for Diagnostic Use. <i>Journal of Clinical Medicine</i> , 2021, 10, 1580.	2.4	7
13	Comparison of Throat Washings, Nasopharyngeal Swabs and Oropharyngeal Swabs for Detection of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 653.	3.3	20
14	Nectin-1 Expression Correlates with the Susceptibility of Malignant Melanoma to Oncolytic Herpes Simplex Virus In Vitro and In Vivo. <i>Cancers</i> , 2021, 13, 3058.	3.7	6
15	Systematic Evaluation of Fluorination as Modification for Peptide-Based Fusion Inhibitors against HIV-1 Infection. <i>ChemBioChem</i> , 2021, 22, 3443-3451.	2.6	4
16	Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations. <i>GMS Infectious Diseases</i> , 2021, 9, Doc02.	0.8	1
17	Zoonotic spillover infections with Borna disease virus 1 leading to fatal human encephalitis, 1999-2019: an epidemiological investigation. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 467-477.	9.1	96
18	A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2. <i>Clinical Oral Investigations</i> , 2020, 24, 3707-3713.	3.0	80

#	ARTICLE	IF	CITATIONS
19	Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using minipools of RNA prepared from routine respiratory samples. <i>Journal of Clinical Virology</i> , 2020, 127, 104381.	3.1	43
20	Successful containment of Covid-19 outbreak in a large maternity and perinatal center while continuing clinical service. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 560-564.	2.6	37
21	Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality. <i>PLoS ONE</i> , 2020, 15, e0243967.	2.5	11
22	The neuropathology of fatal encephalomyelitis in human Borna virus infection. <i>Acta Neuropathologica</i> , 2019, 138, 653-665.	7.7	57
23	Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses. <i>Cancers</i> , 2019, 11, 651.	3.7	12
24	Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA. <i>Frontiers in Immunology</i> , 2019, 10, 2.	4.8	8
25	Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1/2 inhibitor ruxolitinib. <i>Bone Marrow Transplantation</i> , 2019, 54, 762-764.	2.4	0
26	Fatal Encephalitic Borna Disease Virus 1 in Solid-Organ Transplant Recipients. <i>New England Journal of Medicine</i> , 2018, 379, 1377-1379.	27.0	106
27	Inhibition of HIV-1 infection by human pegivirus type 1-derived peptides is affected by human pegivirus type 1 genotype and HIV-1 coreceptor tropism. <i>Aids</i> , 2018, 32, 1951-1957.	2.2	4
28	Peptide Paratope Mimics of the Broadly Neutralizing HIV-1 Antibody b12. <i>ChemBioChem</i> , 2017, 18, 647-653.	2.6	11
29	Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells. <i>Immunology</i> , 2015, 146, 327-338.	4.4	14
30	A subset of human plasmacytoid dendritic cells expresses CD8 $\alpha^+$ upon exposure to herpes simplex virus type 1. <i>Frontiers in Microbiology</i> , 2015, 6, 557.	3.5	10
31	Ligand selectivity of a synthetic CXCR4 mimetic peptide. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4050-4055.	3.0	10
32	Mimicking Protein-Protein Interactions through Peptide-Protein Interactions: HIV-1 gp120 and CXCR4. <i>Frontiers in Immunology</i> , 2013, 4, 257.	4.8	13
33	Technologies for measuring HIV-1 drug resistance. <i>HIV Clinical Trials</i> , 2002, 3, 227-236.	2.0	8
34	Genotypic drug resistance interpretation systems—the cutting edge of antiretroviral therapy. <i>AIDS Reviews</i> , 2002, 4, 148-56.	1.0	14